Last updated: February 14, 2026
Overview of the Drug
NDC 00078-0337 is the identifier for Erythropoetin Alfa (Epogen, Procrit), a recombinant human erythropoietin used primarily for anemia management in chronic kidney disease, chemotherapy, and certain surgical settings. It is manufactured by Johnson & Johnson under the brand names Epogen and Procrit.
Market Size and Demand Drivers
-
Prevalence of Indications: Approximately 37 million people worldwide suffer from chronic kidney disease (CKD), with 1.2 million in the U.S. requiring erythropoiesis-stimulating agent (ESA) therapy. Cancer patients receiving chemotherapy constitute a sizable segment, adding to the demand.
-
Treatment Adoption Trends: The use of erythropoietin has increased due to guidelines promoting anemia management, offsetting the decline caused by safety concerns about cardiovascular risks associated with ESAs.
-
Competitive Landscape: Several biosimilars entered the market post-patent expiry in 2017, intensifying competition. Notable biosimilars include Retacrit (Pfizer), Binocrit (Sandoz), and Abseamed (Amgen).
Pricing Dynamics
-
Brand-Name Pricing: Historically, Epogen campaigns ranged from $30 to $120 per dose (approximately 2,500–4,000 units), with annual treatment costs reaching $10,000–$20,000 per patient.
-
Biosimilar Pricing: Biosimilars in the U.S. retail at a 20–30% discount on brand-name prices, with wholesale prices typically around $70–$90 per 1,000 units.
-
Reimbursement Patterns: Medicare and private insurers predominantly reimburse via fee-for-service models, incentivizing cost reduction through biosimilar substitution.
Market Projections
-
Revenue Trends: The U.S. market for ESAs was valued at $1.2 billion in 2022, with a forecast of decline to $950 million by 2027 due to biosimilar adoption and evolving guidelines.
-
Market Shares: Biosimilars captured approximately 35% of ESA sales in 2022, expected to approach 55% by 2025.
-
Geographic Variations: Growth opportunities exist in emerging markets like China and India due to increased CKD and cancer burdens, with projected compound annual growth rates (CAGR) of 5–8%.
Pricing Future Outlook
-
Price Pressure: Continued biosimilar entry will sustain price erosion, with estimates indicating a 10–15% annual decline in per-unit prices for brand-name drugs over the next five years.
-
Potential Premiums: Exclusive formulations or recently approved formulations may command a 10–20% premium above biosmilar prices for specific indications or delivery methods.
-
Market Entry Considerations: Newer formulations with extended dosing intervals or improved safety profiles could capture higher revenue, but existing biosimilar competition constrains pricing flexibility.
Regulatory and Policy Impact
-
Biosimilar Substitution Laws: Increasing adoption facilitated by policies in the U.S. and Europe mandating substitution at pharmacy level could accelerate price declines.
-
Pricing Regulations: Caps or value-based pricing initiatives under Medicare and Medicaid could further suppress prices, especially in public payor segments.
-
Access and Reimbursement Policies: Expanding coverage in developing markets may moderately mitigate price declines but likely won't offset overall downward pressure.
Summary Table of Price Projections (U.S., 2023–2027)
| Year |
Estimated Average Price per 1,000 Units |
Notes |
| 2023 |
$80 |
Current biosimilar competition at 35% market share |
| 2024 |
$72 |
Increased biosimilar penetration |
| 2025 |
$65 |
Biosimilar share rises to 55%, further price reductions |
| 2026 |
$58 |
Market stabilization, potential new formulations |
| 2027 |
$52 |
Continued price erosion, volume growth may offset price decline |
Key Takeaways
-
The drug, Nesbo erythropoetin alfa, faces ongoing price pressure driven by biosimilar competition and evolving reimbursement policies.
-
The total market is declining in value from approximately $1.2 billion in 2022 to below $1 billion by 2027; biosimilars are gaining market share rapidly.
-
Future pricing will stabilize around a 30–40% discount compared to initial brand prices, with potential for marginal premiums for specialized formulations.
-
Geographic expansion into emerging markets offers growth but with lower price points and higher regulatory hurdles.
FAQs
1. How does biosimilar competition impact the market value of NDC 00078-0337?
Biosimilar entry has reduced pricing from initial brand levels by 20–30% and captured over one-third of the market since 2017, leading to significant revenue compression.
2. What factors could alter the current price projections?
Regulatory changes, significant safety data affecting demand, or new innovative formulations offering superior safety or convenience could influence prices.
3. How does the approval process for biosimilars affect market dynamics?
Fast-track approval pathways and interchangeability designations facilitate biosimilar market penetration, accelerating price declines.
4. What are the main market growth areas outside the U.S.?
Emerging markets like China and India are expanding access to ESAs due to rising CKD and cancer burdens, though at lower price points.
5. What developments could preserve higher prices for this drug?
Introduction of formulations with extended dosing intervals, improved safety profiles, or blocking biosimilar access could sustain or increase prices temporarily.
Sources
[1] IQVIA. (2022). Market Overview of the ESA Market.
[2] EvaluatePharma. (2023). Biologics Market Forecasts.
[3] Agency for Healthcare Research and Quality. (2022). Anemia Management Guidelines.
[4] U.S. Food and Drug Administration. (2017). Biosimilar Approval Pathways.
[5] Centers for Medicare & Medicaid Services. (2022). Reimbursement Policies for Biologics.
